Examples of using Increase in cmax in English and their translations into Bulgarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Increase in Cmax and AUC of nortriptyline metabolite.
A decreased body weight by 30 kg results in an increase in Cmax of 45%.
The increase in Cmax is not considered clinically relevant.
Interaction resulting in an approximate 28% increase in Cmax and 55% increase in AUC.
A 3-4-fold increase in Cmax is apparent for women compared to men.
Following once daily subcutaneous dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
A 3-4-fold increase in Cmax is apparent for women compared to men.
Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
No notable increase in Cmax and AUC upon multiple dosing(10 mg/ kg three times daily) was observed.
Co-administration of digoxin, a P-gp substrate,with empagliflozin resulted in a 6% increase in AUC and 14% increase in Cmax of digoxin.
There is a proportional increase in Cmax and AUC from 20 mg to 60 mg, the range of single-dose administrations tested.
Since the administered dose will be 285 mg every two weeks, or 142.5 mg weekly,little increase in Cmax or AUC is expected upon multiple dosing in the clinical setting.
The average increase in Cmax of olanzapine after the administration of fluvoxamine in non-smokers was 54%, and for men who smoke, 77%.
Multiple once daily dosing of mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine.
A modest increase in Cmax(28%) was observed for zidovudine when administered with lamivudine, however overall exposure(AUC) was not significantly altered.
Accumulation in Ctrough was observed(7- to 14-fold) and little or no increase in Cmax or AUC was observed following weekly SC administration over a dose of 200 to 400 mg.
The average increase in Cmax of olanzapine in blood plasma after application of fluvoxamine is 54% in nonsmoking women and 77% in male smokers.
Inhibition of OATP1B1/1B3 transporters by co-administration with rifampicin resulted in a 75% increase in Cmax and a 35% increase in AUC of empagliflozin.
There is a dose- proportionate increase in Cmax and AUC values following multiple doses ranging from 0.1-1 mg.
Co-administration of erythromycin(500 mg three times a day), a CYP3A4 inhibitor, with vardenafil(5 mg)resulted in a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax.
A modest increase in Cmax(28%) was observed for zidovudine when administered with lamivudine, however overall exposure(AUC) is not significantly altered.
For example, diltiazem(360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor,led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in Cmax.
A modest increase in Cmax(28%) was observed for zidovudine when administered with lamivudine, however overall exposure(AUC) is not significantly altered.
In a pooled analysis, females had a higher netupitant exposure compared to males; there was a 1.31-fold increase in Cmax, a 1.02 fold increase for AUC and a 1.36 fold increase in half-life.
An increase in Cmax(26%) and AUC(29%) was observed in elderly subjects(24 subjects≥ 65 years of age) relative to younger subjects(24 subjects 18- 45 years of age).
A 70% increase in Cmax and 30% increase in AUC of digoxin, a P-gp substrate, were observed when administered with a single dose of 180 mg rolapitant.
Results from a dedicated clinical study showed that patients with severe renal impairment(eGFR≤ 29 mL/min/1.73 m2),had a 29% increase in exposure(AUCinf), a 21% increase in Cmax, and a 22% decrease in CL/F compared to matching healthy subjects.
The increase in Cmax and AUC values was less than dose-proportional between 28 mg and 56 mg or 84 mg, but it was nearly dose proportional between 56 mg and 84 mg.
Breast cancer resistance protein(BCRP) and P-glycoprotein substrates Administration of regorafenib(160 mg for 14 days) prior to administration of a single dose of rosuvastatin(5 mg), a BCRP substrate, resulted in a 3.8-fold increase in mean exposure(AUC)of rosuvastatin and a 4.6-fold increase in Cmax.